Meningitis shot delivers dose of good cheer for CanSino
The company has defied a broader slowdown in the vaccine industry with its latest earnings report, after its flagship drug was cleared for use in a wider age group Key…
FAST NEWS: CanSino’s quarterly revenue rises, but loss also widens
The Latest: CanSino Biologics Inc. (6185.HK; 688185.SH) reported Monday its revenue rose 13.7% year-on-year to about 114 million yuan ($15.7 million) in the first quarter, while its net loss widened 21.9% to…
China’s mRNA pioneer Stemirna faces post-Covid reinvention test
The biopharma company that led the way in Chinese mRNA research is battling a wave of lawsuits and financial woes, including court limits on its founder’s spending Key Takeaways: Flush…
FAST NEWS: CanSino receives Gates Foundation grant to develop polio vaccine
The latest: CanSino Biologics Inc. (6185.HK; 688185.SH) announced on Tuesday it has entered into a grant agreement with the Bill & Melinda Gates Foundation, which will provide over $2 million to support…
FAST NEWS: CanSino’s revenue plunges as demand dries up for Covid vaccines
The latest: CanSino Biologics Inc. (6185.HK; 688185.SH) announced on Wednesday it recorded a net loss of 1.28 billion yuan ($176 million) in the first half of this year, reversing a 16.04…
Fosun Pharma, CanSino take different paths as Covid lift fade
The pair of companies that got strong shots from different Covid vaccines are telling different stories in their latest quarterly results as the pandemic draws down Key Takeaways: Fosun Pharma’s…
CSPC Pharma wins China’s mRNA vaccine race, but just not fast enough
Drugmaker CSPC Pharma gets the green light to produce China’s first homegrown mRNA vaccine, but the breakthrough comes too late in the pandemic to impress investors Key Takeaways: News of…
